Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · ANI Pharmaceuticals (ANIP)

ANI Pharmaceuticals Reports Record Q3 Revenue of $227.8 Million and Raises 2025 Guidance

Positive Impact 4 of 5 earnings Written later

ANI Pharmaceuticals reported third-quarter 2025 net revenues of $227.8 million, up 53.6% from a year earlier, and GAAP net income attributable to common shareholders of $26.3 million, or $1.13 per diluted share, compared with a loss of $1.27 per share in the prior-year quarter. The company raised its full-year 2025 total net revenue guidance to $854 million to $873 million and its adjusted non-GAAP EBITDA guidance to $221 million to $228 million, which points to higher expected results for shareholders.

Key points

  • Q3 2025 net revenues were $227.8 million, up 53.6% from $148.3 million in Q3 2024.
  • Cortrophin Gel net revenues were $101.9 million, up 93.8% year over year.
  • GAAP diluted EPS was $1.13 versus a loss of $1.27 a year earlier; adjusted non-GAAP diluted EPS was $2.04.
  • 2025 total net revenue guidance was raised to $854 million to $873 million, from $818 million to $843 million; ILUVIEN net revenue was $16.6 million in the quarter, which the company said was pressured by reduced Medicare access.

The filing

CompanyANI Pharmaceuticals (ANIP)
Form8-K, current report
Filed with the SECNov 7, 2025, 6:54 AM ET
Accession number0001023024-25-000107

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 6:57 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 07, 2025.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.